LY3164530 is a bispecific antibody that targets mesenchymal-epithelial transition factor (MET) and EGFR for treating advanced and metastatic cancer that recently underwent phase I trials [53]. This evidence concerns the gene EGFR and metastatic malignant neoplasm.